10-K: Schrdinger, Inc. Reports Full Year 2023 Results, Highlights Growth in Software and Drug Discovery

Schrdinger, Inc. announces its full year 2023 financial results, showcasing a 20% increase in total revenue and a net income of $40.7 million.

Summary

• Schrdinger, Inc. reported a 20% increase in total revenue for 2023, reaching $216.7 million, compared to $181.0 million in 2022.
• The company achieved a net income of $40.7 million in 2023, a significant turnaround from a net loss of $149.2 million in 2022.
• Software revenue grew by 17% to $159.1 million in 2023, driven by broad adoption in the biopharmaceutical industry and expansion in materials science.
• Drug discovery revenue increased by 27% to $57.5 million in 2023, primarily due to milestone achievements from collaborative programs.
• The company had 222 customers with an annual contract value (ACV) of at least $100,000, representing 83% of total ACV.
• There were 54 customers with an ACV of at least $500,000 and 27 customers with an ACV of at least $1.0 million.
• Customer retention rate for customers with an ACV of at least $100,000 was 92% and for customers with an ACV of at least $500,000 was 98%.

Sentiment

Score: 8

Explanation: The document presents a strong financial performance with significant revenue growth and a return to profitability. The company's strategic focus on both software and drug discovery, along with its strong customer base and pipeline of proprietary programs, suggests a positive outlook. However, the company also acknowledges the risks associated with drug development and competition, which tempers the overall sentiment.

Positives

• The company experienced significant growth in both software and drug discovery revenue.
• The company achieved profitability in 2023, a major improvement from previous years.
• The company has a strong customer base, with high retention rates and increasing numbers of large customers.
• The company is advancing its proprietary drug discovery programs, with two candidates in Phase 1 clinical trials and another expected to enter Phase 1 by the end of 2024.
• The company has a strong cash position of $468.8 million, which is expected to fund operations for at least the next 24 months.

Negatives

• The company has a history of significant operating losses, although it achieved profitability in 2023.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or other issues.
• The company faces intense competition in both the software and drug discovery markets.
• The company's quarterly and annual results may fluctuate significantly, which could adversely impact the value of its common stock.

Risks

• The company may not be able to sustain profitability.
• The company may not be able to increase sales of its software or revenue from drug discovery collaborations.
• The company may not be successful in developing and commercializing drug products.
• The company may require additional capital to fund its operations.
• The company may face delays in clinical trials or regulatory approvals.
• The company may face competition from other companies in the software and drug discovery markets.
• The company may experience security breaches or disruptions to its information technology systems.

Future Outlook

The company anticipates continued growth in software revenue driven by increased adoption in the biopharmaceutical industry and expansion in materials science. The company also plans to progress its proprietary drug discovery programs and evaluate strategic collaborations to maximize their clinical and commercial potential.

Management Comments

• The company is the leader in the field of physics-based computational drug discovery, and we believe our computational platform is far ahead of that of our nearest competitors.
• Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we anticipate that this scaling-up will drive future revenue growth.
• We believe that the development candidates discovered using our platform have a higher probability of successfully progressing through clinical development than the industry average.

Industry Context

The document highlights the increasing adoption of computational methods in drug discovery and materials science, positioning Schrdinger as a leader in this space. The company's focus on physics-based simulations and integration with machine learning is presented as a key differentiator from traditional methods and competitors relying solely on AI.

Comparison to Industry Standards

• The company's software is used by all of the top 20 pharmaceutical companies, measured by 2022 revenue, indicating a strong position in the industry.
• The company's customer retention rate of 92% for customers with an ACV of at least $100,000 and 98% for customers with an ACV of at least $500,000 suggests a high level of customer satisfaction and value.
• The company's average tenure of 19 years with its 10 largest software customers in 2023 demonstrates the long-term relationships and value of its platform.
• The company's MALT1 inhibitor, SGR-1505, has shown better potency in biochemical and cell-based assays compared to JNJ-6633, a MALT1 inhibitor advanced into Phase 1 clinical development by Johnson & Johnson.
• The company's WEE1/MYT1 inhibitor, SGR-3515, demonstrated an improved selectivity profile compared to AZD1775 from AstraZeneca and ZN-c3 from Zentalis Pharmaceuticals, Inc.

Related Party Transactions

• The company paid consulting fees to a member of its board of directors.
• The company received funds under agreements with the Bill and Melinda Gates Foundation and Gates Ventures, LLC.

Stakeholder Impact

• Shareholders: The company's return to profitability and growth in revenue is positive for shareholders.
• Employees: The company is committed to providing employees with competitive compensation and benefits.
• Customers: The company is focused on providing high-quality software solutions and support to its customers.
• Collaborators: The company is committed to advancing its collaborative programs and maximizing the value of its partnerships.

Next Steps

• The company plans to progress the development of its proprietary drug discovery programs, including SGR-1505, SGR-2921 and SGR-3515.
• The company expects to submit an IND to the FDA for SGR-3515 in the first half of 2024.
• The company plans to initiate a Phase 1 clinical trial of SGR-3515 by the end of 2024.
• The company plans to continue to advance new programs where it can leverage its computational platform to discover novel molecules.
• The company plans to strategically evaluate on a program-by-program basis advancing them into preclinical and clinical development itself, entering into collaborations to co-develop them with leading industry partners, or out-licensing them to maximize their clinical and commercial opportunities.

Key Dates

Keywords

Schrdinger, software, drug discovery, computational platform, biopharmaceutical, materials science, clinical trials, revenue, milestones, ACV, MALT1 inhibitor, CDC7 inhibitor, WEE1/MYT1 inhibitor